About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
AMRN - Amarin Corporation p...| Previous Close | $18.10 | Open | |
| Volume | Market Cap | 6.041B | |
| Yield | Last Dividend |
| Vascepa Growth Will Power Amarin Stock W... | 02/14/20 |
| Vascepa's growth trajectory will sustain robust momentum in 2020, and as it does, Amarin stock will stay in rally mode. | |
| Amarin's Vascepa Is a Great Story Filled... | 02/13/20 |
| The biggest unknown weighing on Amarin stock is how long the decision to take Vascepa will be up to patients, rather than experts. | |
| Will Positive Patent News Send Amarin St... | 02/12/20 |
| The magic seems to have abandoned Amarin Corporation ( AMRN ) , as the stock is down 15% since the start of 2020. The reason? The drug maker is bearin... | |
| Bears Are Now in Control of Amarin Stock... | 02/12/20 |
| Bears are in control of Amarin stock, and selling pressure has driven the price down. But Vascepa will drive huge success for Amarin in 2020. | |
| Does the Recent Amarin Stock Pullback Pu... | 02/06/20 |
| Amarin stock is struggling, and that's been the case even before the stock market pulled back. Here's how AMRN looks now. | |
| Amarin (AMRN) Stock Sinks As Market Gain... | 01/30/20 |
| In the latest trading session, Amarin (AMRN) closed at $19.04, marking a -1.4% move from the previous day. | |
| Amarin Stock Will Deliver More Upside fo... | 01/28/20 |
| As Vascepa's competition dwindles and the drug gains market share, AMRN stock could be in for some significant upside in 2020. | |
| Avoid the ???FOMO??? Hype with Amarin St... | 01/27/20 |
| Amarin stock is drawing attention after its sole drug, Vascepa, got FDA approval for an expanded label. But can the company prove its claims? | |
| Amarin Stock is Still Fully Valued Despi... | 01/27/20 |
| AMRN stock sits close to its December high, as the recent good news on its Vascepa drug is already discounted in the share price. | |
| Why Amarin Stock Is Poised for a Healthy... | 01/17/20 |
| During the past year, Amarin stock has been a laggard. But this could change in 2020 with the company's new drug poised for long-term growth. | |
| Does Amarin Corporation plc's (NASDAQ:AM... | 01/16/20 |
| In 2014 John Thero was appointed CEO of Amarin Corporation plc (NASDAQ:AMRN). First, this article will compare CEO??? | |
| AstraZeneca???s Loss is Amarin Stock???s... | 01/14/20 |
| AstraZeneca is stopping a large clinical study of its fish-oil-derived heart drug, Epanova. That???s good news for Amarin and AMRN stock. | |
| Amarin's stock surges, as rival drugs fr... | 01/13/20 |
| Shares of Amarin Corp. PLC rose 4.8% in active afternoon trading Monday, after makers of drugs that rival Amarin's Vascepa, which is used to lower the... | |
| Amarin Stock Is Surging as Rival Makers ... | 01/13/20 |
| AstraZeneca and Acasti Pharma each disclosed disappointing results from cardiovascular drugs derived from fish or krill oil. Amarin???s stock took off... | |
| Amarin Stock Bouncing Back After Revised... | 01/10/20 |
| Amarin stock is set for growth with Vascepa approval and sales outlook for 2020 predicting revenue will eventually hit billions of dollars. | |
| All Bets Are Off for Amarin Stock | 01/10/20 |
| Much of the upside from flagship drug Vascepa is already priced into Amarin stock. Wait for a pullback before buying AMRN stock. | |
| Amarin Posts '19 Preliminary Results, Gi... | 01/08/20 |
| Amarin's (AMRN) Vascepa sales witness strong growth. The trend is anticipated to continue in 2020. However, the operating expense guidance for 2020 wa... | |
| New hope for investors as Amarin (AMRN) ... | 01/07/20 |
| Though Amarin Corporation (NASDAQ: AMRN) has been showing signs of recovery since last year, after staying low for several years, the stock has a long... | |
| Amarin Provides Update to 2019 Results, ... | 01/07/20 |
| Amarin Corporation provided a business update, including an update of preliminary 2019 results and additional 2020 financial guidance. The post Amarin... | |
| Is Amarin Stock a Top Pick for 2020? | 01/06/20 |
| Amarin stock has been on fire in 2019, but the reaction to its latest news was discouraging. Is that a buying opportunity or a warning sign? | |
| Amarin Stock Primed for New Highs | 01/06/20 |
| Amarin stock is beating the indices and its sector ETFs for a reason. Its chart suggests that there is an exciting move brewing. | |
| Health for Patients, Wealth for Investor... | 12/31/19 |
| On the heels of a long-awaited FDA approval, Amarin stock is just what the doctor ordered. Here's what you can expect from AMRN in 2020. | |
| Amarin Stock Will Keep Powering Higher I... | 12/30/19 |
| The days of 50%-plus annual gains for Amarin stock are over, but that doesn't mean it's done moving higher. It should keep climbing in 2020. | |
| Amarin Stock is at Sky-High Levels Alrea... | 12/20/19 |
| Amarin stock Is at sky high levels assuming all the good news. The FDA drug approval was already built into the AMRN stock price. | |
| Amarin Has the Kind of Future Worth the ... | 12/18/19 |
| A disappointing label verdict from the FDA has Amarin investors taking profits, but there???s reasons to be optimistic. | |
| After Amarin Snags Vascepa Label Expansi... | 12/16/19 |
| Christmas came early for Amarin Corporation plc (NASDAQ: AMRN ) with the FDA's approval of an expanded label for its fish oil pill Vascepa ahead of a ... | |
| Amarin Gains on FDA Approval of Vascepa ... | 12/16/19 |
| Amarin (AMRN) gains as FDA approves a label expansion of Vascepa to reduce cardiovascular risk. | |
| IBI Blogs On Amarin: What The Label Expa... | 12/13/19 |
| As you guys know, the FDA just approved Vascepa of Amarin Corporation (AMRN). I did a coverage inside Integrated BioSci Investing, a community of expe... | |
| Amarin gets FDA approval for new Vascepa... | 12/13/19 |
| Amarin Corp. received U.S. approval to market its drug Vascepa to reduce the risk of cardiovascular events in people with high triglyceride levels, ac... | |
| Buy rating | 02/18/20 |
| Citigroup upgrades from Neutral to Buy rating and lowers Price Target from $27.00 to $24.00 | |
| Hold rating | 01/06/20 |
| JP Morgan initiates coverage with Neutral rating and announces Price Target of $22.00 | |
| Hold rating | 12/16/19 |
| Stifel downgrades from Buy to Hold rating and lowers Price Target from $28.00 to $26.00 | |
| Underperform rating | 12/16/19 |
| Oppenheimer maintains Underperform rating and raises Price Target from $7.00 to $8.00 | |
| Underperform rating | 11/20/19 |
| Oppenheimer initiates coverage with Underperform rating and announces Price Target of $7.00 | |
| Hold rating | 11/18/19 |
| Citi downgrades from Buy to Neutral rating and raises Price Target from $23.00 to $27.00 | |
| Buy rating | 10/31/19 |
| Aegis Capital initiates coverage with Buy rating and announces Price Target of $23.00 | |
| Hold rating | 10/15/19 |
| Goldman Sachs initiates coverage with Neutral rating and announces Price Target of $17.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Big Data Kornacki & Zhou | Zhou Academy | 85.00 % | Subscribe |
| Options Eagle | George | 72.00 % | Follow |
| Alpha Swing Trades | Jonathan | 69.00 % | Follow |
| Option short-term trading [Unusual] | Debashis K | 66.00 % | Subscribe |
| Swingers Corner | Akemi Mokoto | 43.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
